← Eichor
Study identifier: NCT07182227 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

PS-002 for the Treatment of IgA Nephropathy in Adults

Condition: Immunoglobulin A (IgA) Nephropathy  ·  Sponsor: Purespring Therapeutics Limited

PhasePhase 1/Phase 2
Planned participants32
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite receiving current standard-of-care treatment. Participants will be monitored for up to one year after receiving PS-002 and invited to take part in a long-term follow-up study (total follow-up: 5 years).

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Operations  ·  +44 (0)20 3855 6324  ·  contact@purespringtx.com

Always discuss trial participation with your own doctor first.

Locations (10)

University of Miami HospitalMiami, Florida, United StatesRecruiting
The Johns Hopkins HospitalBaltimore, Maryland, United StatesRecruiting
Manchester University NHS Foundation TrustManchester, Greater Manchester, United KingdomRecruiting
Salford Royal Hospital, Northern Care Alliance NHS Foundation TrustManchester, Greater Manchester, United KingdomRecruiting
Leicester General HospitalLeicester, Leicestershire, United KingdomNot Yet Recruiting
Nottingham University Hospitals NHS TrustNottingham, Nottinghamshire, United KingdomRecruiting
Southmead HospitalBristol, United KingdomRecruiting
Cardiff and Vale University Health BoardCardiff, United KingdomNot Yet Recruiting
Royal Infirmary of Edinburgh Clinical Research FacilityEdinburgh, United KingdomRecruiting
The Royal London HospitalLondon, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07182227